H.C. Wainwright lowered the firm’s price target on Insmed (INSM) to $230 from $240 and keeps a Buy rating on the shares. The firm says that while the discontinuation of Insmed’s chronic rhinosinusitis without nasal polyps program is disappointing, the news does not offer a significant readthrough to the remainder of the company’s platform.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM: